167P - Efficacy of EGFR-TKIs for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Non-Small Cell Lung Cancer
Therapy
Biological Therapy
Presenter Yongmei Liu
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors Y. Liu1, Y. Zhang1, L. Zhang2, B. Liu3, X. Zhou1, Y. Li1, L. Zhou1, Y. Gong1, Y. Wang1, Y. Lu1
  • 1Department Of Thoracic Cancer, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN
  • 2Department Of Medical Oncology, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 3Pulmonary Tumor Ward, Sichuan Cancer Hospital, 610041 - Chengdu/CN

Abstract

Background

Due to the low epidermal growth factor receptor (EGFR) mutation rate of squamous cell carcinoma (SQC) of lung, the efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) for lung SQC with EGFR mutations is unclear. The aim of this study was to examine the efficacy of EGFR-TKIs for these patients.

Methods

We retrospectively analyzed 45 patients with advanced or recurrent lung SQC harboring EGFR mutation who were treated with EGFR-TKIs from 3 cancer centers to investigate the efficacy. Then a pooled analysis on the efficacy of EGFR-TKIs was performed in 115 patients including 70 patients selected from 25 published reports.

Results

In our multicenter study, for the SQC patients treated with EGFR-TKIs, the objective response rate (ORR), the disease control rate (DCR), the median progression free survival (PFS) and median overall survival (OS) were 42.2%, 75.6%, 5.1 months and 17.2 months, respectively. In pooled analysis, the ORR, DCR, PFS and OS of SQC patients were 39.1%, 71.3%, 5.6 months and 15.0 months, respectively.

Conclusions

Comparing with historical data, EGFR-TKIs seem to be less effective in EGFR-mutated SQC than in adenocarcinoma (ADC). Some EGFR-mutant SQC could obtain clinical benefit from EGFR-TKIs. Further study is needed to identify this part of patients.

Clinical trial identification

Legal entity responsible for the study

West China Hospital, Sichuan University

Funding

West China Hospital, Sichuan University

Disclosure

All authors have declared no conflicts of interest.